Challenge to be first in a series to crowdsource Alzheimer’s data for new disease insights .
The IP & Science Business of Thomson Reuters has announced a strategic initiative with NuMedii. The companies will leverage high-quality data, knowledge and predictive technologies to identify therapeutic candidates with the greatest probability for clinical success.
In this special guest feature, Shahbaz Ali of Tarmin takes a look at the commoditization of data and how aggregated data has evolved to the extent of being so crucial and proprietary that its value is unparalleled and irreplaceable to the organization. [Read More...]